{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:21:58Z","timestamp":1783999318525,"version":"3.55.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.molmed.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T20:12:12Z","timestamp":1753733532000},"page":"19-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["From pathophysiology to treatment in transthyretin cardiac amyloidosis"],"prefix":"10.1016","volume":"32","author":[{"given":"\u00c2nia","family":"Correia-Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ribeiro-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lino","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Paulo","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-8447","authenticated-orcid":false,"given":"Henrique","family":"Girao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.07.002_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","article-title":"Diagnostic imaging of cardiac amyloidosis","volume":"17","author":"Martinez-Naharro","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0010","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.molmed.2025.07.002_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob. Heart"},{"key":"10.1016\/j.molmed.2025.07.002_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0021-9258(18)72655-0","article-title":"Electrophoretic study of the blood protein response in tuberculosis","volume":"143","author":"Seibert","year":"1942","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI101335","article-title":"An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins","volume":"21","author":"Kabat","year":"1942","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.07.002_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0022-2836(71)90218-X","article-title":"An X-ray study of the subunit structure of prealbumin","volume":"61","author":"Blake","year":"1971","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0040","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/10408363.2024.2350379","article-title":"Transthyretin mutagenesis: impact on amyloidogenesis and disease","volume":"61","author":"Almeida","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0045","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"(2008) Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.molmed.2025.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2025.07.002_bb0055","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10741-021-10164-z","article-title":"The genetics of cardiac amyloidosis","volume":"27","author":"Arno","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.molmed.2025.07.002_bb0060","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","article-title":"Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis","volume":"27","author":"Morfino","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.molmed.2025.07.002_bb0065","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","article-title":"A new era for understanding amyloid structures and disease","volume":"19","author":"Iadanza","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0070","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/prot.26399","article-title":"Analysis of amyloidogenic transthyretin mutations using continuum solvent free energy calculations","volume":"90","author":"Hartmann","year":"2022","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"10.1016\/j.molmed.2025.07.002_bb0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/00007890-199804150-00010","article-title":"Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy","volume":"65","author":"Pomfret","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0080","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2025.07.002_bb0085","article-title":"Simulations of nucleation and elongation of amyloid fibrils","volume":"130","author":"Zhang","year":"2009","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.molmed.2025.07.002_bb0090","doi-asserted-by":"crossref","first-page":"20914","DOI":"10.1073\/pnas.0710152105","article-title":"Prion detection by an amyloid seeding assay","volume":"104","author":"Colby","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0095","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0105","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0110","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.molmed.2025.07.002_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","article-title":"Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis","volume":"18","author":"Koike","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0125","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1073\/pnas.0400062101","article-title":"Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture","volume":"101","author":"Reixach","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0130","article-title":"Ruptured bullae: a case of transthyretin cardiac amyloidosis","volume":"13","author":"Dayco","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.molmed.2025.07.002_bb0135","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archinte.1988.00380030168027","article-title":"endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement","volume":"148","author":"Pellikka","year":"1988","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","article-title":"Cardiac amyloidosis: the need for early diagnosis","volume":"27","author":"Oerlemans","year":"2019","journal-title":"Neth. Hear. J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0150","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-024-02522-2","article-title":"Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?","author":"Bellofatto","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00441-016-2431-9","article-title":"Cardiac fibrosis in myocardial infarction\u2014from repair and remodeling to regeneration","volume":"365","author":"Talman","year":"2016","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.molmed.2025.07.002_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbrc.2022.12.027","article-title":"Pro-inflammatory cytokine secretion induced by amyloid transthyretin in human cardiac fibroblasts","volume":"642","author":"Magaud","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2025.07.002_bb0170","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3892\/ol.2016.5545","article-title":"Transthyretin regulates the migration and invasion of JEG-3 cells","volume":"13","author":"Gong","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.molmed.2025.07.002_bb0175","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/path.2618","article-title":"Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy","volume":"219","author":"Misumi","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13104-023-06491-z","article-title":"Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis","volume":"16","author":"Moreno-G\u00e1zquez","year":"2023","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.molmed.2025.07.002_bb0185","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/cvr\/cvae189","article-title":"Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF\/HFmrEF","volume":"120","author":"Tubben","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.molmed.2025.07.002_bb0190","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1096\/fj.04-2022fje","article-title":"Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in familial amyloid polyneuropathy","volume":"19","author":"Sousa","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0200","doi-asserted-by":"crossref","first-page":"H149","DOI":"10.1152\/ajpheart.00073.2021","article-title":"Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression","volume":"321","author":"Dittloff","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0205","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1172\/JCI31044","article-title":"ECM remodeling in hypertensive heart disease","volume":"117","author":"Berk","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.07.002_bb0210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.addr.2021.03.021","article-title":"Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies","volume":"173","author":"Liu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molmed.2025.07.002_bb0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1161\/CIRCRESAHA.115.303567","article-title":"Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction","volume":"115","author":"Heidt","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.07.002_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1144049","article-title":"Cellular environment of TTR deposits in an animal model of ATTR\u2014Cardiomyopathy","volume":"10","author":"Teixeira","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0225","first-page":"1016","article-title":"Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages","volume":"147","author":"Liu","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0230","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ajpath.2015.12.017","article-title":"Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis","volume":"186","author":"Frunza","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0235","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.bpj.2016.09.010","article-title":"Biochemical and electrophysiological modification of amyloid transthyretin on cardiomyocytes","volume":"111","author":"Sartiani","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0240","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15207","article-title":"Transthyretin deposition alters cardiomyocyte sarcomeric architecture, calcium transients, and contractile force","volume":"10","author":"Dittloff","year":"2022","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.molmed.2025.07.002_bb0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bpc.2013.06.003","article-title":"The amyloid-cell membrane system. The interplay between the biophysical features of oligomers\/fibrils and cell membrane defines amyloid toxicity","volume":"182","author":"Cecchi","year":"2013","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10741-023-10380-9","article-title":"Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy","volume":"29","author":"Wu","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.molmed.2025.07.002_bb0255","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.molmed.2025.07.002_bb0260","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jmb.2008.07.029","article-title":"Structural insight into pH-induced conformational changes within the native human transthyretin tetramer","volume":"382","author":"Palaninathan","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0265","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2025.07.002_bb0270","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jmb.2006.11.076","article-title":"Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin","volume":"366","author":"Pasquato","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0275","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1074\/jbc.M809354200","article-title":"The endoplasmic reticulum-associated degradation of transthyretin variants is negatively regulated by BiP in mammalian cells","volume":"284","author":"Susuki","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.07.002_bb0285","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00018-019-03357-1","article-title":"Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration","volume":"77","author":"Ibrahim","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0290","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.chembiol.2016.09.001","article-title":"Endoplasmic reticulum proteostasis influences the oligomeric state of an amyloidogenic protein secreted from mammalian cells","volume":"23","author":"Chen","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0295","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0300","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0305","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0310","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2","volume":"9","author":"Halle","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/13506129.2015.1007497","article-title":"Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B","volume":"22","author":"Moreira","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuro.2013.08.013","article-title":"Pro-oxidative effects of aggregated transthyretin in human Schwannoma cells","volume":"39","author":"Fong","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.molmed.2025.07.002_bb0325","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00401-002-0574-0","article-title":"Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-\u03baB activation","volume":"104","author":"Matsunaga","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0330","first-page":"691","article-title":"Investigation of AGE, their receptor and NF-kappaB activation and apoptosis in patients with ATTR and Gelsolin amyloidosis","volume":"25","author":"Anan","year":"2010","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0335","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways","volume":"21","author":"Sousa","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0340","doi-asserted-by":"crossref","first-page":"31752","DOI":"10.1074\/jbc.M113.469858","article-title":"Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells","volume":"288","author":"Nunes","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0345","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0350","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7621","article-title":"Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients","volume":"9","author":"Schonhoft","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0365","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/13506129.2024.2404073","article-title":"Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis","volume":"31","author":"Pedretti","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0370","first-page":"1101","article-title":"Large transthyretin aggregates in plasma of ATTR amyloidosis patients: future clinical implications","volume":"9","author":"Fontana","year":"2024","journal-title":"Basic Transl. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0375","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis","volume":"75","author":"Hanna","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0380","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.molmed.2025.07.002_bb0385","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/HCO.0000000000000841","article-title":"Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies","volume":"36","author":"Alreshq","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0390","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/anec.12018","article-title":"The findings of electrocardiography in patients with cardiac amyloidosis","volume":"18","author":"Cheng","year":"2013","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0395","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s44156-023-00028-7","article-title":"British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis","volume":"10","author":"Moody","year":"2023","journal-title":"Echo Res. Pract."},{"key":"10.1016\/j.molmed.2025.07.002_bb0405","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0002-9149(83)80139-8","article-title":"Myocardial texture characterization by two-dimensional echocardiography","volume":"51","author":"Bhandari","year":"1983","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0410","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.molmed.2025.07.002_bb0415","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14797\/mdcvj.1061","article-title":"Clinical clues and diagnostic workup of cardiac amyloidosis","volume":"18","author":"Gill","year":"2022","journal-title":"Methodist. Debakey Cardiovasc. J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0420","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0425","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0430","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.molmed.2025.07.002_bb0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","article-title":"Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0440","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0445","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12350-017-1059-9","article-title":"Imaging cardiac innervation in amyloidosis","volume":"26","author":"Slart","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0450","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11886-018-0976-9","article-title":"Can nuclear imaging techniques predict patient outcome and guide medical management in hereditary transthyretin cardiac amyloidosis?","volume":"20","author":"Algalarrondo","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.molmed.2025.07.002_bb0455","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.molmed.2025.07.002_bb0460","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry\u2013based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.07.002_bb0465","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0470","first-page":"93","article-title":"Evolving strategies in cardiac amyloidosis: from mechanistic discoveries to diagnostic and therapeutic advances","volume":"43","author":"Stein-Merlob","year":"2025","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.molmed.2025.07.002_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1154594","article-title":"Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials","volume":"10","author":"Tomasoni","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0485","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0490","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0495","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.molmed.2025.07.002_bb0500","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0505","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0510","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2025.07.002_bb0515","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0520","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.molmed.2025.07.002_bb0525","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.07.002_bb0530","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0535","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.07.002_bb0540","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0545","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.1095","article-title":"Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101","volume":"45","author":"Van Der Meer","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2025.07.002_bb0555","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2018.09.007","article-title":"Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR","volume":"120","author":"Saelices","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2025.07.002_bb0560","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0565","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.molmed.2025.07.002_bb0570","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-019-1000-1","article-title":"Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series","volume":"14","author":"Waddington-Cruz","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molmed.2025.07.002_bb0575","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13506129.2024.2391842","article-title":"Brain MRI in patients with V30M hereditary transthyretin amyloidosis","volume":"31","author":"Sousa","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0580","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0585","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1471-4159.2007.04828.x","article-title":"Transthyretin enhances nerve regeneration","volume":"103","author":"Fleming","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0590","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/13506129.2018.1564903","article-title":"Electrophysiological demyelinating features in hereditary ATTR amyloidosis","volume":"26","author":"Ohashi","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0595","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4049\/jimmunol.1800736","article-title":"Transthyretin stimulates tumor growth through regulation of tumor, immune, and endothelial cells","volume":"202","author":"Lee","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0600","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","article-title":"Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy","volume":"87","author":"Koike","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2025.07.002_bb0605","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp-2011-301582","article-title":"Transthyretin Val30Met familial amyloid polyneuropathy: a considerably different clinical picture and natural course in endemic and non-endemic areas","volume":"83","author":"Ikeda","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.molmed.2025.07.002_bb0610","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241273079","article-title":"Efficacy and safety of patisiran for ATTRv-PN: a systematic review and meta-analysis","volume":"17","author":"Huang","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.molmed.2025.07.002_bb0615","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/acn3.52158","article-title":"Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis","volume":"11","author":"Chao","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0620","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2025.07.002_bb0625","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.stemcr.2013.10.003","article-title":"Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis","volume":"1","author":"Leung","year":"2013","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.molmed.2025.07.002_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2023.103215","article-title":"Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation","volume":"72","author":"Bonilauri","year":"2023","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.molmed.2025.07.002_bb0635","article-title":"Misfolding of transthyretin in vivo is controlled by the redox environment and macromolecular crowding","volume":"301","author":"Jayaweera","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.07.002_bb0640","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.07.002_bb0645","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000213761","article-title":"Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster","volume":"6","author":"Berg","year":"2009","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.molmed.2025.07.002_bb0650","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1460-9568.2007.05728.x","article-title":"Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis","volume":"26","author":"Pokrzywa","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36357-5","article-title":"Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening","volume":"8","author":"Tsuda","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.07.002_bb0660","doi-asserted-by":"crossref","first-page":"E7710","DOI":"10.1073\/pnas.1801117115","article-title":"Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans","volume":"115","author":"Madhivanan","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0665","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.3390\/ijms22179488","article-title":"In vitro and in vivo effects of serpinA1 on the modulation of transthyretin proteolysis","volume":"22","author":"Bezerra","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.07.002_bb0670","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neurobiolaging.2008.04.001","article-title":"The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems","volume":"31","author":"Santos","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.molmed.2025.07.002_bb0675","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1038\/s41467-021-27416-z","article-title":"Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis","volume":"12","author":"Slamova","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.07.002_bb0680","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/labinvest.2011.195","article-title":"Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease","volume":"92","author":"Ueda","year":"2012","journal-title":"Lab. Investig."},{"key":"10.1016\/j.molmed.2025.07.002_bb0685","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fphys.2019.00338","article-title":"Contributions of animal models to the mechanisms and therapies of transthyretin amyloidosis","volume":"10","author":"Ibrahim","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0690","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.molmed.2025.07.002_bb0695","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.07.002_bb0700","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s43044-025-00625-3","article-title":"Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis","volume":"77","author":"Huang","year":"2025","journal-title":"Egypt Heart J."},{"key":"10.1016\/j.molmed.2025.07.002_bb0705","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.molmed.2025.07.002_bb0710","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.molmed.2025.07.002_bb0715","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol. Ther."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:26:14Z","timestamp":1768407974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1471491425001686"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.07.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From pathophysiology to treatment in transthyretin cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}